Genenta Science S.p.A. stock surged after ANEMOCYTE partnership. Discover temferon's cancer trial updates and what’s next.

Genenta & Anemocyte ink partnership to advance off-the-shelf LVV Plasmid DNA production: Milan Monday, October 27, 2025, 14:00 Hrs [IST] Genenta Science, a pioneer company in immu ...

The Class 12 Biology sample paper covers topics like competition, recombinant DNA technology, immunity, and population ...

A new platform developed at Scripps Research enables fast, scalable protein evolution. This potentially opens the door to new ...

The partnership leverages Genenta's robust and well-tested LVV Plasmid DNA technology, a platform developed from the foundational research of Professor Luigi Naldini, co-founder of Genenta. This ...

People looking to lose weight and lower their blood sugar may someday be able to get a single injection that turns their ...

Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today ...

Investing.com -- Genenta Science (NASDAQ:GNTA) stock soared 241.8% in premarket trading Friday after announcing a strategic collaboration with ANEMOCYTE focused on off-the-shelf lentiviral vector ...

CHARLOTTETOWN, Prince Edward Island & WORCESTER, Mass., November 06, 2025--This partnership provides a fully integrated ...

NexCAR19, the world’s first humanised CAR-T therapy developed in India, has made gene therapies affordable and accessible ...

Imunon is focusing TheraPlas on developing treatments for aggressive, hard-to-treat cancers, starting with ovarian. Its lead ...